PCSK9 antibody marketing application received notification
October 9, 2024
Source: drugdu
55
On September 29, 2024, two acceptance numbers for Junshi Biosciences's PCSK9 antibody marketing application were notified, indicating that they have not been approved (possibly due to voluntary withdrawal or pending approval).
In April 2023, Junshi Biosciences received 4 acceptance numbers for its PCSK9 antibody market application, of which 2 were notified this time, and the other 2 have not yet received results. Four acceptance numbers involve two specifications (pre filled syringes, pre filled automatic syringes) and two indications. This two notifications indicate that a certain specification or indication has not been approved.
The competition for PCSK9 targets is particularly fierce. In addition to antibodies from Amgen and Sanofi, PCSK9 antibodies from Sinovac Biotech and PCSK9 siRNA from Novartis have already been approved for marketing. Among them, Novartis' PCSK9 siRNA only needs to be administered once every six months. For this target, there are more differentiated products under development, including Merck's PCSK9 oral macrocyclic peptide and Lilly's PCSK9 in vivo gene editing.
Source: https://pharm.jgvogel.cn/c1447501.shtml
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Collaborating with 10 Indian AI startups October 16, 2024
- 460 million! Migraine innovative equipment company completes Series B financing October 16, 2024
- Progress has been made in the construction of HSV-1 oncolytic virus where Wuhan virus is located October 16, 2024
- Pfizer’s innovative drug HYMPAVZI ™ Mataximab hncq has been approved by the FDA for the treatment of hemophilia A and hemophilia B October 16, 2024
- The “wolf” is really here, and the elimination of zombie approvals has begun October 16, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
